McKesson (MCK) Introduces FDA-Approved Prostate Cancer Drug [Yahoo! Finance]
McKesson Corporation (MCK)
Last mckesson corporation earnings: 2/4 07:00 am
Check Earnings Report
US:NYSE Investor Relations:
investor.mckesson.com
Company Research
Source: Yahoo! Finance
selected by Accord BioPharma, Inc. as an exclusive specialty pharmacy provider for CAMCEVI (leuprolide) 42mg injection emulsion for subcutaneous use. CAMCEVI is a gonadotropin-releasing hormone (GnRH) agonist indicated for the treatment of adult patients with advanced prostate cancer. CAMCEVI was approved by the FDA on May 25, 2021. The availability of the FDA-approved drug is expected to significantly solidify McKesson's foothold in the global prostate cancer treatment space. Significance of the Availability Per McKesson, CAMCEVI is an important advancement in oncology, which is expected to improve patients' long-term outcomes. McKesson's management believes that the availability of the convenient therapy will likely provide an option to treat patients with advanced prostate cancer. Industry Prospects Per a report by Grand View Research, the global prostate cancer therapeutics market size was estimated at $12.12 billion in 2022 and is anticipated to expand at a CAGR of 8.
Show less
Read more
Impact Snapshot
Event Time:
MCK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MCK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MCK alerts
High impacting McKesson Corporation news events
Weekly update
A roundup of the hottest topics
MCK
News
- Healthcare IT Market Set for 17.80% CAGR Surge, Reaching USD 736.09 billion by 2031 | SkyQuest Technology [Yahoo! Finance]Yahoo! Finance
- Can McKesson (MCK) Steadily Compound Earnings? [Yahoo! Finance]Yahoo! Finance
- McKesson (MCK) Stock Slides as Market Rises: Facts to Know Before You Trade [Yahoo! Finance]Yahoo! Finance
- McKesson Corporation Announces First Quarter Fiscal 2025 Earnings Release DateBusiness Wire
- McKesson ideaShare Ignites and Inspires Independent Community Pharmacies [Yahoo! Finance]Yahoo! Finance
MCK
Earnings
- 5/7/24 - Miss
MCK
Sec Filings
- 6/21/24 - Form ARS
- 6/21/24 - Form DEFA14A
- 6/21/24 - Form DEF
- MCK's page on the SEC website